Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types

Immune checkpoint inhibitor (ICI) therapy provides a valuable treatment option for many cancer patients but is associated with immune-related adverse events (irAEs) that can involve any organ system. Managing irAEs can be a challenge, as these AEs differ from those associated with conventional chemo...

Descripción completa

Detalles Bibliográficos
Autor principal: Wood, Laura S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522659/
https://www.ncbi.nlm.nih.gov/pubmed/33014517
http://dx.doi.org/10.6004/jadpro.2019.10.2.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522659/
https://www.ncbi.nlm.nih.gov/pubmed/33014517
http://dx.doi.org/10.6004/jadpro.2019.10.2.13

Ejemplares similares